Of note is that Abs against CD47 that block the CD47/SIRPα axis are in multiple clinical trials as a cancer immunotherapeutic alone and in combination with other therapeutics and have shown efficacy in certain human cancers (21–25), and in reducing vascular inflammation of carotid arteries in a small retrospective analysis of patient trial data (26). Here, CD47 is linked to cancer.